BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
The management of Abbott India Ltd. is confident of returning to historical double-digit growth rate, as Indian pharma market is showing signs of recovery at the start of FY22.
Its strategy is to provide differentiated products with innovative formulations, delivery solutions and newer packaging, including life cycle management of legacy brands.
The company has invested to provide holistic prescription to over-the-counter solutions in all its focus therapies.
The management believes shaping of key therapies is critical to deliver market-beating growth, which is achieved by in-depth analysis of market trends along with key marketing capabilities and strengths.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR